Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Estrogen Receptor Positive|HER2/Neu Positive|Postmenopausal|Premenopausal|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Refractory Breast Carcinoma|Refractory Hormone Receptor Positive Breast Carcinoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Everolimus|OTHER: Laboratory Biomarker Analysis|DRUG: Letrozole|BIOLOGICAL: Trastuzumab
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)